- Massive Funding Milestone: Colossal Biosciences raises $200M in Series C funding, boosting its valuation to $10.2B as it advances efforts to revive extinct species like the woolly mammoth, Tasmanian tiger, and dodo.
- Breakthrough Technologies: The company leverages CRISPR gene-editing and artificial wombs to spearhead de-extinction while planning to commercialize these innovations for healthcare, agriculture, and fertility applications.
- Diverse Revenue Streams: Colossal anticipates billions in annual revenue through technology spin-offs, government collaborations for conservation, and the sale of biodiversity credits.
Colossal Biosciences, a groundbreaking biotechnology company, has raised $200 million in its Series C funding round, propelling its valuation to $10.2 billion. This latest investment, led by TWG Global, underscores growing confidence in the company’s ambitious mission to revive extinct species, including the woolly mammoth, Tasmanian tiger, and dodo bird. This comes just two years after its previous funding round, which valued the company at $1.5 billion.
The funding surge reflects investor interest in Colossal’s rapid advancements in de-extinction technologies. The company employs a genome-editing approach using CRISPR to modify the DNA of living relatives of extinct species. For the woolly mammoth, for example, scientists are editing Asian elephant cells to replicate mammoth traits. Once completed, the altered cells will be implanted into egg cells and carried to term by a surrogate elephant. Colossal claims it has already mapped genomes for the mammoth and thylacine, placing it on track to achieve its 2028 target for the species’ revival.
Central to Colossal’s strategy is the development of innovative technologies like artificial wombs, which could revolutionize animal reproduction and human fertility treatments. The company plans to commercialize these breakthroughs by spinning off three distinct businesses within the next two years. Two subsidiaries have already emerged: Breaking, a platform focused on plastic degradation, and Form Bio, a computational biology platform. Both ventures have secured substantial seed funding, showcasing Colossal’s potential beyond de-extinction.
In addition to private investments, Colossal collaborates with governments on conservation projects. While the company offers its technology to preserve endangered species at no cost, some nations are exploring de-extinction projects for culturally or spiritually significant animals. This collaboration may evolve into a revenue stream as interest in biodiversity conservation grows globally.
Looking ahead, Colossal anticipates revenue from three primary sources: technological applications, government partnerships, and biodiversity credits—an emerging market similar to carbon credits. If successful, the company’s innovations could generate billions in annual recurring revenue, making it a pioneer in both conservation and biotechnology. With its latest funding, Colossal is positioned to redefine the intersection of science and sustainability.
